Lucentis Versus Mitomycin C During Glaucoma Surgery

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wills Eye
• Collaborators: Genentech, Inc.; Novartis Pharmaceuticals
• Treatments: Mitomycin; Mitomycins; Ranibizumab

Criteria

Inclusion Criteria:

• 18 yrs or older

• patients requiring first time glaucoma filtering surgery

• phakic or pseudophakic

• must provide written informed consent and comply with study assignments

Exclusion Criteria:

• Pregnant, lactation or premenopausal women not using adequate contraception.

• Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle, penetrating keratoplasty.

• Abnormality preventing reliable applanation tonometry in each eye.

• Current infection or inflammation in either eye.

• Enrolled in another investigational study.